Seven Bridges is named to MIT Technology Review’s annual 50 Smartest Companies list

June 21, 2016

CAMBRIDGE, Mass. — 21 June 2016 — Seven Bridges, the biomedical data analysis company, has been named to MIT Technology Review’s 2016 list of 50 Smartest Companies. To make the list, a company must have innovative technology and a business model that is both practical and ambitious, with the result that it has set the agenda in its field over the past 12 months.

Jason Pontin, publisher and editor in chief, states, “Each year we identify 50 companies that are ‘smart’ in the way they create new opportunities. Some of this year’s stars are large companies that are using digital technologies to redefine industries, while others wrestle with technological changes. Also on the list are ambitious startups looking to make their mark in an existing marketplace or create a new market entirely.”

“We are honored to be included and recognized for our role in driving precision medicine initiatives forward,” said James Sietstra, President, Seven Bridges. “Our technology helps enable scalable and collaborative biomedical data analysis. We are excited to help researchers around the world collaborate on their work and learn from vast quantities of genomic data.”

The list is included in MIT Technology Review’s annual business issue, which is available online now at www.technologyreview.com and on newsstands worldwide on July 5, 2016.

About MIT Technology Review

Founded at MIT in 1899, MIT Technology Review is an independent media company whose mission is to explain the commercial, social, and political impact of new technologies. Readers are a global audience of business and thought leaders, innovators and early adopters, entrepreneurs and investors. We’re first to report on a broad range of new technologies, informing our audiences about how important breakthroughs will impact their careers and lives.

About Seven Bridges

Seven Bridges is the biomedical data analysis company accelerating breakthroughs in genomics research for cancer, drug development and precision medicine. The scalable, cloud-based Seven Bridges Platform empowers rapid, collaborative analysis of millions of genomes in concert with other forms of biomedical data. Thousands of researchers in government, biotech, pharmaceutical and academic labs use Seven Bridges, including three of the largest genomics projects in the world: U.S. National Cancer Institute’s Cancer Genomics Cloud pilot, the Million Veteran Program and Genomics England’s 100,000 Genomes Project. As the NIH’s only commercial Trusted Partner, Seven Bridges authenticates and authorizes access to one of the world’s largest cancer genomics dataset. The company has offices in Cambridge, Mass.; Belgrade; London and San Francisco.

Press Contacts
Amanda Orr, +1-202-459-1304
Laurie Gibson, +1-650-815-1438
media@sevenbridges.com

David W.M. Sweeney
MIT Technology Review
+1-617-475- 8018